Sorafenib, a multi-kinase inhibitor of VEGF/VEGFR and RAF/MEK/ERK pathways that exhibits anti-angiogenic and anti-proliferative activities, is recommended as a standard first-line drug for patients with advanced-stage HCC. The gene discussed is MAP2K7; the disease is hepatocellular carcinoma.